Total Shoulder ArthroplastyNCT07770165
Continuous Interscalene Blocks and Rebound Pain
A study testing Continuous interscalene nerve block and Interscalene Block in people with Total Shoulder Arthroplasty and Reverse Total Shoulder Arthroplasty, run by University of Calgary at 1 site in Canada.
Trial summary
The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Interscalene Analgesia
- What is being tested?
- Continuous interscalene nerve block and Interscalene Block
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 154 participants
- Where
- 1 siteCanada
- Study dates
- Oct 2026to May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged >18 years of age
- ASA I-III
- Scheduled for elective ambulatory total shoulder arthroplasty.
Who cannot join
- ASA IV
- Revision surgery
- Contraindication to regional anesthesia (such as allergy to local anesthetics, systemic anticoagulation, local infection)
- Preoperative chronic pain or opioid use
- Preoperative drug dependency
- Severe respiratory disease or contralateral diaphragmatic paralysis
- Patient refusal.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
South Health Campus
Calgary, Alberta, T3M 1M4
Joanna Dr Fifen, MD, PhD, 403-956-3690, Joanna.Fifen@albertahealthservices.ca
Joanna Fifen, MD, PhD
About this study
Official title: Evaluation of the Effect of Continuous Interscalene Blocks on Rebound Pain Compared to Single-Shot Interscalene Blocks in Total Shoulder Arthroplasty : A Randomized-Controlled Trial
The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty.
Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale [NRS] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."
Read the detailed description
The number of patients requiring shoulder replacements for many different indications, including osteoarthritis, cuff arthropathy and acute fractures has continually grown in the last 15 years, as suggested by a recent international meta-analysis. While there is no designated Canadian database specific to total shoulder arthroplasty compiled by the Canadian Institute for Health Information (CIHI), international data suggests that the expansion of the indications for reverse total shoulder replacements has contributed to the increase in the total amount of patients that undergo such procedure, with an estimated growth of 6-15% between 2011 and 2019. Moreover, there has also been a four-fold increase in the proportion of outpatient shoulder arthroplasty cases in an ACS-NSQIP database from 2015-2019, without a notable increase in adverse patient events, highlighting a shift towards a more ambulatory approach to total shoulder arthroplasty (TSA).
As this procedure becomes mostly ambulatory, new challenges arise regarding the best pain management modality to limit the overall need for opioids and reduce their side effects including respiratory depression, pruritis, nausea and vomiting, as well as increasing patient satisfaction and recovery. There are multiple anesthetic techniques described in the literature to aid in multimodal analgesia, the most commonly used being the interscalene block (ISB), as a single-shot (sISB) or as a continuous infusion (cISB), often combined with multimodal analgesia with dexamethasone and dexmedetomidine. Other techniques include superior trunk blocks, as well as suprascapular nerve block, often used as an alternative when respiratory complications are a major concern due to phrenic nerve blockade. Most regional analgesia techniques detailed above have shown superior pain management compared to local infiltration alone.
Although the interscalene block is clearly established as standard of care for all patients undergoing shoulder surgery, numerous studies have compared the efficacy of sISB versus catheter-based cISB, with variable results favoring either modality in terms of pain management, opioid consumption and patient-related side effects. A more recent systematic review and meta-analysis of over 1000 patients in 20 trials on the effects of single-injection vs. continuous brachial plexus blocks for shoulder surgeries on patient-reported outcomes published in June 2026 has highlighted better pain management for cISB than sISB, especially during the 12- to 48-hour period, although most of the regimens showing better analgesia also included patient-controlled boluses. Notably, mean pain at rest was lower in the cISB group, with a particular benefit in the 24-48 hour period, a period where the concept of "rebound pain" can occur with single-shot modalities.
This concept has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale [NRS] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance.", with an estimated occurrence of 49.6%. Some identified contributors were younger patients, female gender, surgery involving bone, the absence of IV dexamethasone, as well as upper limb surgery. A possible explanation relies on a "supply-vs-demand" mismatch, where the possible analgesic block could be of insufficient length compared to the patient's needs, especially in the at-risk populations. A study realized in 2007 on femoral nerve block proved that prolonging a nerve block with a catheter based infusion did reduce the apparition of rebound pain. This concept has yet to be formally evaluated in upper limb surgeries and blocks, including in total shoulder arthroplasty.
- Conditions
- Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Interscalene Analgesia, Interscalene Blocks, Interscalene Nerve Block, Orthopedic Surgery Patients
- Being tested
- Continuous interscalene nerve block, Interscalene Block
- Keywords
- Interscalene, Nerve Block, Catheter, Continuous Interscalene Block, Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Rebound Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous interscalene nerve blockDrug
This Interventional Group will receive a continuous interscalene block via a catheter for a duration of 48 hours with ropivacaine 0.2% at a fixed 5 mL/hour rate.
Interscalene BlockDrug
This control group will receive a single shot interscalene block with 20 mL of ropivicaine 0.2%.
| Study group | Role | What they receive |
|---|---|---|
| Single Shot Interscalene Block | Active comparator | This Control Group will receive a single-shot interscalene block, which is considered one of the standard of care analgesic modality for shoulder surgery. Receives: Drug: Interscalene Block |
| Continuous Interscalene Block | Experimental | This Interventional Group will receive a continuous interscalene block via a catheter for a duration of 48 hours with ropivacaine 0.2% at a fixed 5 mL/hour rate. Receives: Drug: Continuous interscalene nerve block |
What is being measured
The primary outcome is the main question the study is designed to answer.
incidence of Rebound pain within 96 hours postoperatively
The incidence of Rebound Pain, defined as an NRS score of < 3 during an effective block to an NRS > 7 within 24 hours of block resolution. This will be analyzed as a binary variable (yes/no)
Measured: This outcome will be measured within 24 hours of block resolution, for up to 96 hours after the initial block realization.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study startOct 2026 (estimated)
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Total Shoulder ArthroplastyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a pragmatic randomized controlled, parallel group, single-blinded trial comparing a single-shot interscalene block (control group) to a catheter-based continuous interscalene block (treatment group) placed preoperatively in total shoulder arthroplasty patients.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 154 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Calgary
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07770165
- Sponsor's protocol ID
- REB26-1309
- Status last verified
- Jul 2026
- First submitted
- 12 Aug 2026
- Last updated
- 19 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
https://www.sciencedirect.com/science/article/pii/S2950553424000856
https://www.sciencedirect.com/science/article/pii/S0972978X20301756?via%3Dihub#bib20
https://www.nysora.com/regional-anesthesia/techniques/upper-extremity/intescalene/ultrasound-guided-interscalene-brachial-plexus-block/
https://www.ovid.com/jnls/co-anesthesiology/fulltext/10.1097/aco.0000000000000651~rebound-pain-after-regional-anesthesia-in-the-ambulatory
https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.16583
https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.70249
Williams BA, Bottegal MT, Kentor ML, Irrgang JJ, Williams JP. Rebound pain scores as a function of femoral nerve block duration after anterior cruciate ligament reconstruction: retrospective analysis of a prospective, randomized clinical trial. Reg Anesth Pain Med. 2007 May-Jun;32(3):186-92. doi: 10.1016/j.rapm.2006.10.011.
PubMed 17543812Barry GS, Bailey JG, Sardinha J, Brousseau P, Uppal V. Factors associated with rebound pain after peripheral nerve block for ambulatory surgery. Br J Anaesth. 2021 Apr;126(4):862-871. doi: 10.1016/j.bja.2020.10.035. Epub 2020 Dec 31.
PubMed 33390261Rhyner P, Cachemaille M, Goetti P, Rossel JB, Boand M, Farron A, Albrecht E. Single-bolus injection of local anesthetic, with or without continuous infusion, for interscalene brachial plexus block in the setting of multimodal analgesia: a randomized controlled unblinded trial. Reg Anesth Pain Med. 2024 May 7;49(5):313-319. doi: 10.1136/rapm-2023-104681.
PubMed 37541683Hussain N, Goldar G, Ragina N, Banfield L, Laffey JG, Abdallah FW. Suprascapular and Interscalene Nerve Block for Shoulder Surgery: A Systematic Review and Meta-analysis. Anesthesiology. 2017 Dec;127(6):998-1013. doi: 10.1097/ALN.0000000000001894.
PubMed 28968280Kim HJ, Koh KH, Park JI, Kim YJ, Kim MJ, Kim H, Kim H, Ro YJ, Koh WU. Comparison of the Analgesic Efficacy between Arthroscopically Placed Continuous Suprascapular Nerve Block and Ultrasound-guided Continuous Superior Trunk Block: A Double-blinded Randomized Controlled Trial. Anesthesiology. 2023 Nov 1;139(5):591-601. doi: 10.1097/ALN.0000000000004691.
PubMed 37450621Pai B H P, Bohaczuk S, Jinadu S, Hong J, Echevarria G, Lai YH, Chen J, Cagle PJ, Flatow EL, Rosenblatt M. Comparison of analgesic efficacy of continuous perineural catheter, liposomal bupivacaine, and dexamethasone as an adjuvant for interscalene block in total shoulder arthroplasty: a triple-blinded randomized controlled trial. J Shoulder Elbow Surg. 2025 Feb;34(2):e81-e92. doi: 10.1016/j.jse.2024.06.014. Epub 2024 Aug 27.
PubMed 39197650Xiao M, Cohen SA, Cheung EV, Freehill MT, Abrams GD. Pain management in shoulder arthroplasty: a systematic review and network meta-analysis of randomized controlled trials. J Shoulder Elbow Surg. 2021 Nov;30(11):2638-2647. doi: 10.1016/j.jse.2021.06.008. Epub 2021 Jul 17.
PubMed 34284094Trudeau MT, Peters JJ, LeVasseur MR, Hawthorne BC, Dorsey CG, Wellington IJ, Shea KP, Mazzocca AD. Inpatient versus outpatient shoulder arthroplasty outcomes: A propensity score matched risk-adjusted analysis demonstrates the safety of outpatient shoulder arthroplasty. J ISAKOS. 2022 Apr;7(2):51-55. doi: 10.1016/j.jisako.2022.01.001. Epub 2022 Jan 25.
PubMed 35546436Woodmass J, Harris S, McRae S, Righolt CH, MacDonald P, Bohm E. Implementation of and findings from a regional shoulder replacement registry. Can J Surg. 2026 Mar 31;69(2):E137-E145. doi: 10.1503/cjs.014624. Print 2026 Mar-Apr.
PubMed 41916651
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effect of Continuous Interscalene Blocks on Rebound Pain Compared to Single-Shot Interscalene Blocks in Total Shoulder Arthroplasty : A Randomized-Controlled Trial
- ClinicalTrials.gov ID
- NCT07770165
- Acronym / sponsor ID
- REB26-1309
- Conditions
- Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Interscalene Analgesia, Interscalene Blocks, Interscalene Nerve Block, Orthopedic Surgery Patients
- Keywords
- Interscalene, Nerve Block, Catheter, Continuous Interscalene Block, Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Rebound Pain
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 154 participants (estimated)
- Lead sponsor
- University of CalgaryUniversity, hospital or other
- Study start
- Oct 2026 (estimated)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 18 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty.
Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale [NRS] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."
Detailed description
The number of patients requiring shoulder replacements for many different indications, including osteoarthritis, cuff arthropathy and acute fractures has continually grown in the last 15 years, as suggested by a recent international meta-analysis. While there is no designated Canadian database specific to total shoulder arthroplasty compiled by the Canadian Institute for Health Information (CIHI), international data suggests that the expansion of the indications for reverse total shoulder replacements has contributed to the increase in the total amount of patients that undergo such procedure, with an estimated growth of 6-15% between 2011 and 2019. Moreover, there has also been a four-fold increase in the proportion of outpatient shoulder arthroplasty cases in an ACS-NSQIP database from 2015-2019, without a notable increase in adverse patient events, highlighting a shift towards a more ambulatory approach to total shoulder arthroplasty (TSA).
As this procedure becomes mostly ambulatory, new challenges arise regarding the best pain management modality to limit the overall need for opioids and reduce their side effects including respiratory depression, pruritis, nausea and vomiting, as well as increasing patient satisfaction and recovery. There are multiple anesthetic techniques described in the literature to aid in multimodal analgesia, the most commonly used being the interscalene block (ISB), as a single-shot (sISB) or as a continuous infusion (cISB), often combined with multimodal analgesia with dexamethasone and dexmedetomidine. Other techniques include superior trunk blocks, as well as suprascapular nerve block, often used as an alternative when respiratory complications are a major concern due to phrenic nerve blockade. Most regional analgesia techniques detailed above have shown superior pain management compared to local infiltration alone.
Although the interscalene block is clearly established as standard of care for all patients undergoing shoulder surgery, numerous studies have compared the efficacy of sISB versus catheter-based cISB, with variable results favoring either modality in terms of pain management, opioid consumption and patient-related side effects. A more recent systematic review and meta-analysis of over 1000 patients in 20 trials on the effects of single-injection vs. continuous brachial plexus blocks for shoulder surgeries on patient-reported outcomes published in June 2026 has highlighted better pain management for cISB than sISB, especially during the 12- to 48-hour period, although most of the regimens showing better analgesia also included patient-controlled boluses. Notably, mean pain at rest was lower in the cISB group, with a particular benefit in the 24-48 hour period, a period where the concept of "rebound pain" can occur with single-shot modalities.
This concept has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale [NRS] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance.", with an estimated occurrence of 49.6%. Some identified contributors were younger patients, female gender, surgery involving bone, the absence of IV dexamethasone, as well as upper limb surgery. A possible explanation relies on a "supply-vs-demand" mismatch, where the possible analgesic block could be of insufficient length compared to the patient's needs, especially in the at-risk populations. A study realized in 2007 on femoral nerve block proved that prolonging a nerve block with a catheter based infusion did reduce the apparition of rebound pain. This concept has yet to be formally evaluated in upper limb surgeries and blocks, including in total shoulder arthroplasty.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- This is a pragmatic randomized controlled, parallel group, single-blinded trial comparing a single-shot interscalene block (control group) to a catheter-based continuous interscalene block (treatment group) placed preoperatively in total shoulder arthroplasty patients.
| Arm | Type | Receives |
|---|---|---|
| Single Shot Interscalene Block | Active comparator | Drug: Interscalene BlockThis Control Group will receive a single-shot interscalene block, which is considered one of the standard of care analgesic modality for shoulder surgery. |
| Continuous Interscalene Block | Experimental | Drug: Continuous interscalene nerve blockThis Interventional Group will receive a continuous interscalene block via a catheter for a duration of 48 hours with ropivacaine 0.2% at a fixed 5 mL/hour rate. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged >18 years of age
- ASA I-III
- Scheduled for elective ambulatory total shoulder arthroplasty.
Key exclusion criteria (7 listed)
- ASA IV
- Revision surgery
- Contraindication to regional anesthesia (such as allergy to local anesthetics, systemic anticoagulation, local infection)
- Preoperative chronic pain or opioid use
- Preoperative drug dependency
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous interscalene nerve blockThis Interventional Group will receive a continuous interscalene block via a catheter for a duration of 48 hours with ropivacaine 0.2% at a fixed 5 mL/hour rate. | Drug | Continuous Interscalene Block |
| Interscalene BlockThis control group will receive a single shot interscalene block with 20 mL of ropivicaine 0.2%. | Drug | Single Shot Interscalene Block |
Primary outcome
incidence of Rebound pain within 96 hours postoperatively
Time frame: This outcome will be measured within 24 hours of block resolution, for up to 96 hours after the initial block realization.
The incidence of Rebound Pain, defined as an NRS score of < 3 during an effective block to an NRS > 7 within 24 hours of block resolution. This will be analyzed as a binary variable (yes/no)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Backgroundhttps://www.sciencedirect.com/science/article/pii/S2950553424000856
- Backgroundhttps://www.sciencedirect.com/science/article/pii/S0972978X20301756?via%3Dihub#bib20
- Backgroundhttps://www.nysora.com/regional-anesthesia/techniques/upper-extremity/intescalene/ultrasound-guided-interscalene-brachial-plexus-block/
- Backgroundhttps://www.ovid.com/jnls/co-anesthesiology/fulltext/10.1097/aco.0000000000000651~rebound-pain-after-regional-anesthesia-in-the-ambulatory
- Backgroundhttps://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.16583
- Backgroundhttps://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.70249
- Background: PubMed 17543812Williams BA, Bottegal MT, Kentor ML, Irrgang JJ, Williams JP. Rebound pain scores as a function of femoral nerve block duration after anterior cruciate ligament reconstruction: retrospective analysis of a prospective, randomized clinical trial. Reg Anesth Pain Med. 2007 May-Jun;32(3):186-92. doi: 10.1016/j.rapm.2006.10.011.
- Background: PubMed 33390261Barry GS, Bailey JG, Sardinha J, Brousseau P, Uppal V. Factors associated with rebound pain after peripheral nerve block for ambulatory surgery. Br J Anaesth. 2021 Apr;126(4):862-871. doi: 10.1016/j.bja.2020.10.035. Epub 2020 Dec 31.
- Background: PubMed 37541683Rhyner P, Cachemaille M, Goetti P, Rossel JB, Boand M, Farron A, Albrecht E. Single-bolus injection of local anesthetic, with or without continuous infusion, for interscalene brachial plexus block in the setting of multimodal analgesia: a randomized controlled unblinded trial. Reg Anesth Pain Med. 2024 May 7;49(5):313-319. doi: 10.1136/rapm-2023-104681.
- Background: PubMed 28968280Hussain N, Goldar G, Ragina N, Banfield L, Laffey JG, Abdallah FW. Suprascapular and Interscalene Nerve Block for Shoulder Surgery: A Systematic Review and Meta-analysis. Anesthesiology. 2017 Dec;127(6):998-1013. doi: 10.1097/ALN.0000000000001894.
- Background: PubMed 37450621Kim HJ, Koh KH, Park JI, Kim YJ, Kim MJ, Kim H, Kim H, Ro YJ, Koh WU. Comparison of the Analgesic Efficacy between Arthroscopically Placed Continuous Suprascapular Nerve Block and Ultrasound-guided Continuous Superior Trunk Block: A Double-blinded Randomized Controlled Trial. Anesthesiology. 2023 Nov 1;139(5):591-601. doi: 10.1097/ALN.0000000000004691.
- Background: PubMed 39197650Pai B H P, Bohaczuk S, Jinadu S, Hong J, Echevarria G, Lai YH, Chen J, Cagle PJ, Flatow EL, Rosenblatt M. Comparison of analgesic efficacy of continuous perineural catheter, liposomal bupivacaine, and dexamethasone as an adjuvant for interscalene block in total shoulder arthroplasty: a triple-blinded randomized controlled trial. J Shoulder Elbow Surg. 2025 Feb;34(2):e81-e92. doi: 10.1016/j.jse.2024.06.014. Epub 2024 Aug 27.
- Individual participant dataSharing planned: No
Related trials for Total Shoulder Arthroplasty
Recruiting
INHANCE Stemless Reverse Shoulder IDE
Arthroplasty, Replacement
Enrolling by invitationObservational study
Subscapularis-Sparing Total Shoulder Arthroplasty
Total Shoulder Arthroplasty
Not yet recruiting
Assessment of Posterior Subluxation of the Humeral Head Using Biplanar Imaging in the Upright Position in Patients Scheduled for Total Shoulder Arthroplasty
Shoulder Arthroplasty
RecruitingObservational study
Comparison Between Exactech Guided Personalized Surgery (GPS) and Conventional Instrumentation of Shoulder Arthroplasty
Technology, Comparison
Not yet recruiting
A Trial to Assess the Safety and Effectiveness of an Anatomic Total Shoulder System
Shoulder Arthroplasty, Total Shoulder Arthroplasty
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous interscalene nerve block and Interscalene Block in people with Total Shoulder Arthroplasty and Reverse Total Shoulder Arthroplasty, run by University of Calgary at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
incidence of Rebound pain within 96 hours postoperatively (time frame: This outcome will be measured within 24 hours of block resolution, for up to 96 hours after the initial block realization.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07770165, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.